OSMI-4 [2260791-14-6]
Katalog-Nummer T12328-10mg
Size : 10mg
Marke : TargetMol
OSMI-4
Copy Product Info
OSMI-4 is a low nanomolar O-GlcNAc transferase (OGT) inhibitor (EC50 of 3 μM in cells) that can be used to study OGT inhibition in different human cell lines.
Cas No. 2260791-14-6
Custom-made molecule. TargetMol’s expert synthesis team delivers cost-effective solutions. Contact us for inquiries. Committed to serving you.
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.45%
ee:100%
Appearance:Solid
Color:White
COA CSFC HNMR LCMS ORP
Product Information
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | OSMI-4 is a low nanomolar O-GlcNAc transferase (OGT) inhibitor (EC50 of 3 μM in cells) that can be used to study OGT inhibition in different human cell lines. |
| Targets & IC50 | OGT:60 nM, OGT:3 μM (EC50) |
| In vitro | Method: HEK293T cells were treated with OSMI-4 (10 μM, 2 hours) and quantitative PCR was performed using primers for the OGT retained intron (intron 4) and spliced exon (exon 4). Result The bar graph shows that OSMI-4 increases retained intron splicing. [1] Method: HEK293T cells were treated with OSMI-4 (20, 50 μM, 24 hours); HEK293T cells were treated with OSMI-4 (0.1, 1, 5, 5, 10, 20 μM, 2, 24, 48 hours); Western blot analysis of total O-GlcNAc was performed. Result O-GlcNAc levels were reduced to a greater extent following OSMI-4 treatment; 24 hours of OSMI-4 treatment of HEK293T cells resulted in a dose-dependent decrease in O-GlcNAc levels, with effects seen with only 5 µM of compound treatment, and these effects could be observed in as little as 2 hours or 48 hours. [1] |
| Molecular Weight | 604.09 |
| Formula | C27H26ClN3O7S2 |
| Cas No. | 2260791-14-6 |
| Smiles | CCOC(=O)CN(Cc1cccs1)C(=O)[C@H](NS(=O)(=O)c1cc2ccc(=O)[nH]c2cc1Cl)c1ccccc1OC |
| Relative Density. | 1.414 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 252.5 mg/mL (417.98 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Saline: 10 mg/mL (16.55 mM), Solution. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (8.28 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||